Nanogroup SA

Nanogroup SA has a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a fully equity-financed operation. The company holds cash and equivalents of PLN 1,079,000, but its current ratio is 0.46, suggesting limited short-term liquidity to cover liabilities. The company's operating cash flow is negative at PLN -938,000, and free cash flow is also negative at PLN -1,618,000, indicating ongoing cash outflows from operations.

Profitability metrics show significant underperformance relative to industry norms. Return on equity is -0.4036 and return on assets is -0.1377, both indicating substantial losses relative to equity and asset base. These figures are well below the typical performance of companies in the Biotechnology & Medical Research industry, which usually exhibit positive returns on equity and assets.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to market-specific risks and limits the ability to offset losses in one area with gains in another.

Growth trajectory is negative, with the company reporting a revenue of PLN 2,000 and significant operating and net losses. The outlook for the current and next fiscal years is not provided, but the historical performance suggests a challenging path to profitability. The company's capital expenditures are negative at PLN -332,000, indicating a reduction in investment in long-term assets.

Risk factors include low liquidity and the absence of long-term debt, which may limit the company's ability to finance operations or expand. The risk assessment indicates low dilution potential, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative cash flows and profitability metrics suggest a high operational risk.

Recent events include the latest financial filing, which discloses the company's poor financial performance. No recent earnings call transcripts or other material events are available in the provided data.

Nanogroup maintains a zero debt-to-equity ratio, ranking above the cohort median and indicating a conservative capital structure.

The company faces low dilution, liquidity, and credit risks, suggesting manageable operational hazards despite current financial performance.

Nanogroup holds a positive book value of 3.19 million PLN, providing a baseline asset cushion for the business.

Operating margin stands at -647.5%, placing Nanogroup in the bottom quartile of its biotechnology cohort peers.

Net margin of -643.5% ranks in the bottom quartile, highlighting extreme profitability challenges relative to industry peers.